ASP Isotopes Shareholder Letter Highlights 50% PET Labs Revenue Surge, Imminent Helium Production, and Stable Isotopes Nearing Commercialization
ASPI sits 23% above its 52-week low of $3.51.
Summary
ASP Isotopes delivered a comprehensive operational update showing PET Labs revenue surging >50%, helium production at Renergen imminent, and stable isotopes nearing commercialization—multiple near-term catalysts that validate its sum-of-the-parts strategy.
Key Events · Earnings and Guidance · ASPI
-
PET Labs Revenue Surges >50%
Organic revenue growth exceeded 50% in 1H 2026 versus 1H 2025, with FY 2026 revenue forecast at ~$14M (up from $6M in 2025) and a 2031 EBITDA target of $50-100M.
-
Helium Production Imminent at Renergen
Helium production is expected to commence before September 30, 2026; Phase 1 annualized helium and LNG revenues are forecast at ~$27M at current prices. Phase 2 construction is set to start in 2H 2026, backed by ~$750M in senior debt commitments.
-
Stable Isotopes Near Commercialization
The Silicon-28 enrichment facility is operating 48 stages at 98% enrichment, with the first 99% shipment expected in 2H 2026. The Ytterbium-176 facility recommenced enrichment in 1Q 2026, and a continuous processing vessel will enable commercial quantities.
-
QLE Note Exchange Simplifies Spin-Off Path
Approximately 50% of outstanding QLE convertible notes were exchanged for ASPI common stock, reducing third-party principal to ~$79.1M. ASPI now holds ~$140.7M principal and 100% of QLE common equity, supporting a potential tax-efficient distribution to shareholders.
Analysis · ASPI · Industrial Applications And Services
The shareholder letter from ASP Isotopes reveals transformative operational momentum across all business units. PET Labs achieved >50% organic revenue growth in 1H 2026, with FY 2026 revenue forecast at ~$14M (up from $6M in 2025) and a 2031 EBITDA target of $50-100M. Helium production at Renergen is expected to commence before September 30, 2026, with Phase 1 annualized revenues of ~$27M at current prices, while Phase 2 construction starts in 2H 2026 backed by ~$750M in senior debt commitments. Meanwhile, the Silicon-28 and Ytterbium-176 enrichment facilities are in final stages of commercial production, with initial shipments expected in 2H 2026. The QLE convertible note exchange simplifies the path to a potential tax-efficient distribution of QLE equity to ASPI shareholders. These updates materially de-risk the investment thesis and validate the company's sum-of-the-parts strategy, with multiple near-term catalysts that could drive significant re-rating.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPI was trading at $4.32 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $540.1M. The 52-week trading range was $3.51 to $14.49. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.